The global infectious disease drug market is projected to grow at a CAGR of over 4% during the forecast period. Infectious diseases transfer from person to person, and bites of insects and animals, through ingestion of contaminated food or water or being exposed to organisms such as bacteria, viruses, parasites, and fungi in the surroundings. The factors that are supporting the growth of the infectious disease drug industry include the increased prevalence of diseases and continuous contributions by the key players in the global infectious diseases drug market.
To Request a Sample of our Report on Global Infectious Disease Drug Market: https://www.omrglobal.com/request-sample/infectious-disease-drug-market
Some of the key players operating in the market across the globe include Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA, among others. These key players are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to sustain in a competitive environment and gain maximum share in the global infectious disease drug market.
In November 2019, Allergan Plc announced the achievement of the Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation for ATM-AVI by the US FDA for the treatment of various infectious diseases, such as ventilator-associated bacterial pneumonia (VABP)/ hospital-acquired bacterial pneumonia (HABP), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI).
In November 2019, Bayer AG expanded the 5-year collaboration with the World Health Organization (WHO) for the R&D activities on the infectious disease such as taeniasis and neurocystercosis, which are the major preventable cause of epilepsy.
In May 2019, Celegen Corp. announced that it has received the Breakthrough Therapy designation to POMALYST (pomalidomide) from the US FDA for the treatment of HIV patients.
In June 2018, Gilead Sciences Inc. and Hookipa partnered and signed a licensing agreement for the development of immunotherapies against HIV and Hepatitis B. Through this agreement both the companies together manufacture arenavirus-based vectors for clinical development by Gilead Sciences Inc.
Current Market Trends Covered in the Global Infectious Disease Drug Market Report:
- Improved healthcare infrastructure along with various reimbursements is positively affecting the infectious disease drug industry.
- Shifting of consumer preferences toward the use of personalized or precision medicines is expected to provide ample growth opportunities to the infectious disease drug market.
- Antibacterial treatment type segment will have significant growth in the market.
- Asia-Pacific region will register a significant growth rate in infectious disease drug market during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Global Infectious Disease Drug Market is Available at: https://www.omrglobal.com/industry-reports/infectious-disease-drug-market
Global Infectious Disease Drug Market – Segmentation
By Disease Type
- Bacterial Disease
- Viral Disease
- Fungal Disease
- Parasitic Disease
By Treatment Type
- Antibacterial
- Antiparasitic
- Antiviral
- Antifungal
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
